AU2009206566A1 - Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib - Google Patents

Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib Download PDF

Info

Publication number
AU2009206566A1
AU2009206566A1 AU2009206566A AU2009206566A AU2009206566A1 AU 2009206566 A1 AU2009206566 A1 AU 2009206566A1 AU 2009206566 A AU2009206566 A AU 2009206566A AU 2009206566 A AU2009206566 A AU 2009206566A AU 2009206566 A1 AU2009206566 A1 AU 2009206566A1
Authority
AU
Australia
Prior art keywords
imatinib
patient
cmin
pharmaceutically acceptable
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009206566A
Other languages
English (en)
Inventor
Yanfeng Wang
Elisabeth Wehrle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009206566(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009206566A1 publication Critical patent/AU2009206566A1/en
Priority to AU2013201993A priority Critical patent/AU2013201993B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009206566A 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib Abandoned AU2009206566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013201993A AU2013201993B2 (en) 2008-01-23 2013-03-26 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
US61/022,945 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013201993A Division AU2013201993B2 (en) 2008-01-23 2013-03-26 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib

Publications (1)

Publication Number Publication Date
AU2009206566A1 true AU2009206566A1 (en) 2009-07-30

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009206566A Abandoned AU2009206566A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib

Country Status (14)

Country Link
US (3) US20100298338A1 (https=)
EP (1) EP2237783B1 (https=)
JP (2) JP5936821B2 (https=)
KR (1) KR101579993B1 (https=)
CN (1) CN101951910B (https=)
AU (1) AU2009206566A1 (https=)
BR (1) BRPI0906504A2 (https=)
CA (1) CA2712087A1 (https=)
ES (1) ES2526537T3 (https=)
MX (1) MX2010008103A (https=)
PL (1) PL2237783T3 (https=)
PT (1) PT2237783E (https=)
RU (1) RU2537223C2 (https=)
WO (1) WO2009094360A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
CN101693031A (zh) * 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
PT2068938E (pt) * 2006-09-22 2011-03-23 Novartis Ag Optimização do tratamento da leucemia filadélfia positiva com o inibidor de tirosina quinase abl imatinib
PE20081157A1 (es) 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno

Also Published As

Publication number Publication date
EP2237783A1 (en) 2010-10-13
WO2009094360A1 (en) 2009-07-30
PT2237783E (pt) 2014-12-23
CA2712087A1 (en) 2009-07-30
JP5936821B2 (ja) 2016-06-22
JP2014094946A (ja) 2014-05-22
US20170035757A1 (en) 2017-02-09
JP2011510086A (ja) 2011-03-31
BRPI0906504A2 (pt) 2015-07-14
JP5881671B2 (ja) 2016-03-09
US20160045501A1 (en) 2016-02-18
US9763944B2 (en) 2017-09-19
CN101951910A (zh) 2011-01-19
RU2537223C2 (ru) 2014-12-27
PL2237783T3 (pl) 2015-04-30
ES2526537T3 (es) 2015-01-13
CN101951910B (zh) 2013-07-17
KR101579993B1 (ko) 2015-12-23
US20100298338A1 (en) 2010-11-25
MX2010008103A (es) 2010-08-23
RU2010134916A (ru) 2012-02-27
EP2237783B1 (en) 2014-11-19
KR20100105778A (ko) 2010-09-29

Similar Documents

Publication Publication Date Title
JP5948246B2 (ja) Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
JP4499359B2 (ja) シグナル変換阻害剤とエポチロン誘導体とを含有してなる組合せ剤
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
WO2018092064A1 (en) Combinations of mdm2 inhibitors and bcl-xl inhibitors
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
CN101180060B (zh) 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合
US20240269136A1 (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
MX2008001971A (es) Combinacion de compuestos organicos.
KR101822492B1 (ko) 3-[(3-｛[4-(4-모르폴리닐메틸)-1h-피롤-2-일]메틸렌｝-2-옥소-2,3-디하이드로-1h-인돌-5-일)메틸]-1,3-티아졸리딘-2,4-디온과 egfr tyr 키나제 억제제 사이의 신규한 회합물

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted